about
Targeting neuropilin 1 as an antitumor strategy in lung cancer.Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study.Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.Intrapleural minocycline pleurodesis for the treatment of primary spontaneous pneumothorax.Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1.Transmission and clinical features of enterovirus 71 infections in household contacts in Taiwan.Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma.Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery.Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer.Simple aspiration and drainage and intrapleural minocycline pleurodesis versus simple aspiration and drainage for the initial treatment of primary spontaneous pneumothorax: an open-label, parallel-group, prospective, randomised, controlled trial.MicroRNA signature predicts survival and relapse in lung cancer.Lipiodol uptake and retention by human hepatoma cells.Functional MR imaging of tumor angiogenesis predicts outcome of patients with acute myeloid leukemia.Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinomaNasopharyngeal carcinoma with cardiac tamponadeCatalase prevents estradiol-induced chondrocyte cytotoxicityTREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancerImprint cytology improves accuracy of computed tomography-guided percutaneous transthoracic needle biopsyEconomic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in TaiwanPleurodesis for primary spontaneous pneumothorax - authors' reply
P50
Q30833416-468D6D9D-3D5F-40C0-BFBB-FB1F5A04C5A9Q33349410-8BD8083C-538D-4D71-BD8F-F5DB4875676DQ34116750-D5380FAD-3517-4501-8B1B-8EC1131CBB0FQ38213843-615867BC-A09C-4207-AAA4-E5B275194D76Q40131305-2FA0D2A3-4F87-4D3A-BDDE-34A1857ADF6EQ40542265-DD976D07-2C68-4BCC-8D56-F40F9093668DQ43539653-53FCD1A2-FB62-45FF-A2EB-ADC76E999F59Q44926653-68341474-800D-4E9C-BBEB-93F3E289D128Q45279361-F6F13C2A-E209-4268-87DE-67EE2FB7A5F9Q45912966-21C41A25-1922-4EA0-8154-75BE4BF8BD78Q53507653-708F1D1E-3070-4A4D-9E05-BD4964F33A37Q53738234-C20F2483-65F9-486D-A4DF-F8E1009B64F9Q54365154-49FBB5DF-A24A-45ED-806D-33F69F098547Q71088888-35A8CA22-3D65-4EED-B9DA-A6A3F7A6106AQ72851181-647DBBAB-A54E-4081-8F68-B4EEB08A00F3Q74371341-5AD323E9-17A7-4C29-9EB0-54B37B1D552EQ80241015-5AAFF0B3-398B-488C-8F21-6263840C1B6AQ81420948-54EE2891-8B13-4A6C-B73D-75E1FB214D3FQ84002796-750F00C4-3C31-4D98-8715-189D89CE415EQ87120698-80CC21A6-91A5-40D5-8795-30EBC92DC928
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Wing-Kai Chan
@ast
Wing-Kai Chan
@en
Wing-Kai Chan
@es
Wing-Kai Chan
@nl
Wing-Kai Chan
@sl
type
label
Wing-Kai Chan
@ast
Wing-Kai Chan
@en
Wing-Kai Chan
@es
Wing-Kai Chan
@nl
Wing-Kai Chan
@sl
prefLabel
Wing-Kai Chan
@ast
Wing-Kai Chan
@en
Wing-Kai Chan
@es
Wing-Kai Chan
@nl
Wing-Kai Chan
@sl
P106
P1153
7403918032
P31
P496
0000-0002-5328-548X